Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Yong Cheng

Yong Cheng

Peking University, China

Title: Comparison of the One-Year Outcomes of Conbercept Therapy Between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy

Biography

Biography: Yong Cheng

Abstract

Objectives: To compare the outcomes of Conbercept therapy between two different angiographic subtypes of Polypoidal Choroidal Vasculopathy (PCV) Methods: Fifty-eight patients of PCV were classified into two phenotypes according to indocyanine green angiography (ICGA). In type-1, both feeder and draining vessels are visible on ICGA and network vessels are numerous. In type-2, neither feeder nor draining vessels are detectable and the number of network vessels is small. The patients were treated with intravitreal Conbercept (IVC) for 3 months. Additional IVC was given at subsequent monthly visits, if needed. The patients were followed-up for 12 months and changes in mean BCVA, central retinal thickness (CRT), serous retinal detachment (SRD), hemorrhage and number of Polypoidal lesions were evaluated. Results: The mean BCVA in type-2 PCV (15.92±9.7614.10±9.07) achieved a significantly greater improvement in than the type-1 (14.10±9.07) at month 12 (p<0.01). And the mean CRT decrease was numerically greater in type-2 (120.44±73.81) compared with type-1 (106.48±72.33) at month 6 (p<0.01) and greater in type-2 (130.21±76.28) compared with type-1 (111.67±79.57) at month 9 (p<0.01). There was no significant difference between the two groups for the decrease in SRF thickness, PED height and regression of polyps from month 3 to 12 (p>0.05). Conclusions: Classification systems for PCV will show differences in presentation, natural history or response to anti-VEGF treatment and might therefore provide a new key to the choice of treatment of the disease.